JP2021527072A5 - - Google Patents

Info

Publication number
JP2021527072A5
JP2021527072A5 JP2020568472A JP2020568472A JP2021527072A5 JP 2021527072 A5 JP2021527072 A5 JP 2021527072A5 JP 2020568472 A JP2020568472 A JP 2020568472A JP 2020568472 A JP2020568472 A JP 2020568472A JP 2021527072 A5 JP2021527072 A5 JP 2021527072A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
protein
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020568472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527072A (ja
JP7373209B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035922 external-priority patent/WO2019236931A1/en
Publication of JP2021527072A publication Critical patent/JP2021527072A/ja
Publication of JP2021527072A5 publication Critical patent/JP2021527072A5/ja
Application granted granted Critical
Publication of JP7373209B2 publication Critical patent/JP7373209B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020568472A 2018-06-08 2019-06-07 がん免疫治療のための組換え単純ヘルペスウイルス Active JP7373209B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682202P 2018-06-08 2018-06-08
US62/682,202 2018-06-08
PCT/US2019/035922 WO2019236931A1 (en) 2018-06-08 2019-06-07 Recombinant herpes simplex virus for cancer immunotherapy

Publications (3)

Publication Number Publication Date
JP2021527072A JP2021527072A (ja) 2021-10-11
JP2021527072A5 true JP2021527072A5 (cg-RX-API-DMAC7.html) 2022-06-15
JP7373209B2 JP7373209B2 (ja) 2023-11-02

Family

ID=67070913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020568472A Active JP7373209B2 (ja) 2018-06-08 2019-06-07 がん免疫治療のための組換え単純ヘルペスウイルス

Country Status (8)

Country Link
US (2) US12329794B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801583B1 (cg-RX-API-DMAC7.html)
JP (1) JP7373209B2 (cg-RX-API-DMAC7.html)
KR (1) KR102906757B1 (cg-RX-API-DMAC7.html)
CN (1) CN112243378B (cg-RX-API-DMAC7.html)
AU (1) AU2019282755B2 (cg-RX-API-DMAC7.html)
CA (1) CA3142073A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019236931A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111635913B (zh) * 2020-06-16 2022-03-04 广东东阳光药业有限公司 构建体及其应用
CN113862229A (zh) * 2020-06-30 2021-12-31 东莞市东阳光生物药研发有限公司 一种重组单纯疱疹病毒及其构建方法
CN113943752A (zh) * 2020-07-15 2022-01-18 东莞市东阳光生物药研发有限公司 构建体、敏感性提高的溶瘤病毒及其应用
CN114075574A (zh) * 2020-08-19 2022-02-22 广东东阳光药业有限公司 构建体、溶瘤病毒及其应用
KR20260066088A (ko) * 2023-08-25 2026-05-12 베링거 잉겔하임 베트메디카 (차이나) 코포레이션 리미티드 조류 백신을 위한 신규한 dev 벡터

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4810042B2 (ja) * 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
EP2140879A1 (en) * 2001-05-09 2010-01-06 M'S Science Corporation Composition and method for treating cancer using herpes virus
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses
EP3217993A1 (en) * 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
US20170319638A1 (en) 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer

Similar Documents

Publication Publication Date Title
US11680248B2 (en) Recombinant herpes simplex virus and use thereof
JP6424145B2 (ja) ウイルス株
JP2021119797A5 (cg-RX-API-DMAC7.html)
Roizman The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors.
Lachmann Herpes simplex virus‐based vectors
Kinchington et al. Herpes simplex virus and varicella zoster virus, the house guests who never leave
Rolinski et al. Immunological aspects of acute and recurrent herpes simplex keratitis
Mody et al. Herpes simplex virus: a versatile tool for insights into evolution, gene delivery, and tumor immunotherapy
AU2001226951A1 (en) Virus strains for the oncolytic treatment of cancer
WO2007052029A1 (en) Oncolytic herpes virus vectors
US12509662B2 (en) Generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
Watanabe Medical application of herpes simplex virus
Nash T cells and the regulation of herpes simplex virus latency and reactivation
US20220002680A1 (en) Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
Hukkanen et al. Host responses to herpes simplex virus and herpes simplex virus vectors
EP3594328A1 (en) Recombinant herpes simplex virus and use thereof
Spencer et al. Herpes simplex virus: A versatile tool for insights into evolution, gene delivery, and tumor immunotherapy
Kim Herpes simplex virus type 1 glycoprotein gm and the membrane associated protein UL11 are required for virus-induced cell fusion and efficient virus entry
Cohrs et al. 2014 Colorado alphaherpesvirus latency symposium
Israyelyan Novel Oncolytic Herpesviruses for Breast Cancer Treatment
Bidula Development of HSV-1 lacking the immunodominant gB498-505 epitope and analyses of the alternative CD8+ T cell response in the murine ocular infection model
Marconi et al. Development and Gene Therapy
BR112019018630B1 (pt) Vírus simplex herpes recombinante, método para obter o vírus simplex herpes recombinante, composição farmacêutica, e uso do vírus simplex herpes recombinante
Harkness Cell type dependent effects on HSV transcription